Affordable drugs, vaccines, and diagnostics, along with domestic biomanufacturing support, are crucial for the middle class and vulnerable groups, according to Union Minister of State for Science and Technology, Dr. Jitendra Singh. He highlighted that the Budget’s focus on cutting-edge technologies and AI-driven reforms will bring long-term relief from healthcare and living expenses, benefiting families dealing with chronic diseases like cancer and diabetes. The Minister noted the significant financial burden on families due to chronic diseases and emphasized the need for large-scale investments in biopharma, diagnostics, vaccines, and gene-based therapies.
India, with over 11-12 crore diabetics and a rising cancer incidence, is set to benefit from the Rs 10,000 crore Biopharma Shakti initiative, positioning the country as a global bio-manufacturing hub. Dr. Singh underlined the importance of expanding capabilities in biologics, biosimilars, vaccines, medical devices, and gene-based technologies to strengthen India’s global standing in the biopharma sector. He likened biotechnology to the next major industrial driver, foreseeing a bio-revolution that encompasses advanced life-science innovations and sustainable practices.
The Budget’s focus on non-communicable diseases and mental health marks a significant shift, with plans to establish new super-speciality institutes for mental health in North India. Additionally, the decision to set up institutes for Ayurveda and pharmaceutical education aims to integrate traditional medicine systems with modern research and healthcare delivery, ensuring broader access to care across the country.
